Combined Chemotherapy with Vinorelbine and Ifosfamide as Third-line Treatment and Beyond of Advanced Non-small Cell Lung Cancer
10.3779/j.issn.1009-3419.2015.06.04
- VernacularTitle:长春瑞滨联合异环磷酰胺三线以后治疗晚期非小细胞肺癌的疗效和不良反应
- Author:
ZHOU YANG
1
;
XU YAN
;
ZHAO JING
;
ZHONG WEI
;
WANG MENGZHAO
Author Information
1. 中国医学科学院中国协和医科大学北京协和医院呼吸内科
- Keywords:
Vinorelbine;
Ifosfamide;
Lung neoplasms
- From:
Chinese Journal of Lung Cancer
2015;(6):351-357
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) should be treated with ifrst-line and second-line chemotherapy or target therapy according to the lung cancer guide-lines. However, no recommended treatments are available atfer failure to these treatments. In our study, the effcacy and safety of combined chemotherapy of vinorelbine and ifosfamide as third-line therapy or beyond for advanced NSCLC was evaluated. Methods A total of 41 patients took a combination of vinorelbine and ifosfamide as third-line or above chemotherapy in Pe-king Union Hospital between May 2010 and May 2014. hTey were pathologically or cytologically conifrmed as having locally advanced or metastatic NSCLC. Clinically measurable lesions existed, and Eastern Cooperative Oncology Group performance status ranged from 0 to 2. No serious complications were observed in the hematopoietic system, and liver and renal functions were normal.Results hTe 41 patients enrolled in this study were given 150 cycles of chemotherapy, of which 23 cycles (15.3%) were delayed or dose-adjusted. Results of the objective response evaluation showed that 3 cases had objective partial response (7.3%) and 25 cases were stable (61.0%). hTe median progression-free survival time was 5.5 months, and the median overall survival time was 10.5 months. Hematological toxicity was the most frequent adverse event. Grade 3/4 neutropenia had 10.7% occurrence; grade 3/4 white blood cell decrease had 8.7%; and grade 3/4 anemia had 8.7%. All adverse events were manage-able, and no drug-related death was found.Conclusion Vinorelbine and ifosfamide as third-line treatment and beyond of NSCLC were well tolerated. Most patients can beneift from this combined chemotherapy. A clinical trial with large samples is necessary to prove whether overall survival will .
